Tranexamic Technologies
Tranexamic Technologies is dedicated to developing transformative therapies based on Tranexamic Acid (TA) and its derivatives. The company focuses on innovative solutions for various medical challenges, including antiviral treatments, cancer therapies, and anti-aging applications. With a strong emphasis on research and collaboration, Tranexamic Technologies aims to enhance health outcomes through groundbreaking medical advancements.
What We Do
Tranexamic Acid (TA)
A synthetic lysine analog used for antifibrinolysis with potential applications in treating viral infections, cancer, and other diseases.
Nasal Spray for Respiratory Viruses
A nasal spray designed to be taken at the first symptoms of respiratory viral infections, aiming to reduce severity and transmission.
Topical Gel for HSV Treatment
A gel containing TA for the topical treatment of Herpes Simplex Virus (HSV) infections.
TA for Cancer Treatment
Research and development of TA as a treatment for various cancers, including triple negative breast cancer and squamous cell carcinoma.
TA for Concussion Treatment
Exploration of TA's benefits in treating mild traumatic brain injury and concussion.
Healthspan Enhancement
Research on the long-term administration of TA to increase lifespan and reduce age-related diseases.
Key People
Paul Stewart
Partner
Frank Murdock
Partner
News & Updates
US Patent 10,792,232
Methods to deliver antifibrinolytic drugs for anti-aging results. Filed Oct. 17, 2017.
US Patent 11,241,405
Methods and Compositions to Enhance a Non-Surgical Medical Treatment. Filed April 4, 2017.
Multiple patents pending
Covering methods and compositions for use of lysine analogs and related agents against cancer, microbes, and aging conditions.